How effective are weight loss injections, really?

You've seen the headlines. Here's what the numbers mean for a real person.

If you've been reading about these medicines, you've probably seen figures like "20% weight loss" and wondered whether that's realistic for someone in your situation, or whether it's a marketing figure drawn from an unusually tidy study population. It's a fair thing to wonder. The trials were conducted in adults with obesity or overweight and at least one weight-related condition, across diverse backgrounds, so the populations aren't as narrow as some pharmaceutical studies. Tirzepatide's SURMOUNT-1 trial randomised 2,539 participants over 72 weeks; the STEP 1 trial for semaglutide involved over 1,900 adults. These aren't tiny datasets.

What the headline averages don't tell you is the spread. Some participants lost considerably more; others lost less. A meaningful minority lost fewer than 5% of their body weight. This isn't a failure of the medicine, it reflects the biological variation in how people respond, and it's one reason a prescriber reviews your case specifically rather than simply approving everyone who applies. The SURMOUNT-1 data, published in the New England Journal of Medicine, remains the most detailed source for tirzepatide's weight outcomes if you want to read the full breakdown.

One honest thing worth saying: if you're here because you've tried a lot of things already and you're tired of being told to "just eat less", that frustration is completely understandable. These medicines work differently from calorie-counting. They change the hormonal signals that govern hunger, which is why many people using them describe the experience not as willpower, but as simply not feeling the same pull towards food they had before.

Which injection is more effective, and does the answer change at higher doses?

Tirzepatide and semaglutide are both licensed in the UK for weight management, but they work through different mechanisms. Semaglutide activates a single gut-hormone receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP) which is why it is sometimes described as a dual agonist. In practical terms, the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity but without diabetes. That gives clinicians the clearest direct comparison yet.

The picture is shifting slightly with the arrival of higher-dose semaglutide. The MHRA approved a 7.2mg semaglutide maintenance dose (and subsequently a dedicated single-dose 7.2mg pen on 14 April 2026) following trial data showing around 20.7% average weight loss over 72 weeks. That begins to close the gap with tirzepatide's highest dose. If you want a more detailed comparison of both options, our guide to the most effective weight loss injection sets out the evidence side by side. Which medicine is appropriate for you is a clinical decision, not one made by a headline figure alone.

Dose also matters within each medicine. Both tirzepatide and semaglutide are started at a low dose to let your body adjust, then increased gradually by your prescriber. The strongest results in the trials came at the highest tolerated maintenance doses. A person using a mid-range dose for a shorter period should reasonably expect a more modest result, which is normal and expected, not a sign the treatment isn't working.

What affects how effective the injection will be for you personally?

Trial averages describe a population. Your result is shaped by a set of individual factors that no trial can pre-calculate for you. The ones that consistently matter in the clinical literature include: how long you continue treatment (weight loss tends to accumulate over the full treatment course, with many people still losing at 52 weeks), how closely the diet and activity guidance is followed, your starting metabolic profile, and whether there are any other medicines or conditions affecting how you respond. If you're trying to understand how effective the weight loss injection is likely to be before committing, our dedicated guide works through the evidence in plain terms.

Adherence is significant. The oral semaglutide trial (OASIS 4, 64 weeks) illustrates this clearly: average weight loss across all participants was around 13.6%, but among those who stayed fully adherent to treatment it was approximately 17%. That gap exists in the injection trials too, even if the published averages smooth it out. If you're considering the tablet as an alternative to injecting, this comparison of tablets and injections covers what the evidence says about each route. A question people often ask alongside that is whether weight loss pills are as effective as injections, and the answer depends on the specific medicine and formulation involved.

Stopping the medicine is also part of the picture. Both NICE and the clinical trial data show that weight tends to return after stopping, which is why these medicines are intended for use within a broader long-term weight management plan rather than a short course. Understanding what a full course involves is worth doing before you start. The NHS sets out its guidance on this clearly, and it's reflected in how prescribers at regulated services structure ongoing treatment reviews.

How does clinical oversight shape the result?

The effectiveness figures from the trials didn't emerge in a vacuum. Participants had regular contact with healthcare teams, their doses were adjusted appropriately, and anyone experiencing serious side effects was supported. Real-world outcomes tend to track closest to trial results when that level of clinical involvement is replicated.

That's the argument for choosing a service carefully, not just cheaply. A prescription issued after a genuine clinical review (one that checks your medical history, current medicines, and weight) is a different thing from a form processed automatically. Our overview of weight loss injections explains what that process looks like in practice, including the identity and weight verification steps that regulated services carry out. The NHS also provides detailed guidance on what responsible prescribing of weight management injections involves, which is useful context whether you're accessing treatment privately or through an NHS pathway.

Our clinical team reviews every consultation personally. For a broader look at the weight management options available through nume (sorry) through our treatment page, you can check your eligibility and start a free consultation there. There are no subscriptions, no automatic renewals, and every repeat order goes through fresh clinical review before anything is dispatched.